Pharmaceuticals, Biotechnology and Life Sciences
Debiopharm International, a Swiss-based global biopharmaceutical company, has started testing its antibiotic afabicin (Debio 1450) for the treatment of staphylococcal bone and joint infections in a clinical phase II study.
Veracyte delivered growth in 2018 and are off to a strong start in 2019, as it posted $92.0 million revenue for full year, an increase of 28%, with net loss of $23.0 million, an improvement 26%.
Cellectis developed engineered GMCSF Knock-Out CAR T-cells through TALEN-mediated gene inactivation, which found to prevent secretion of pro-inflammatory cytokines by monocytes, without compromising CAR T-cell anti-tumor activity, thebiopharmaceutical company said Tuesday in a press release.
Halo Labs and Cannus Partners Inc., have made a deal in whcih Cannus will provide Halo with 1,500 pounds of cannabis product (biomass) per week and in return Halo shall manufacture and supply Cannus 50,000 grams of high-grade distillate per week.
Multi-disciplinary engineering company WHP has secured the design, construction and project management contract for the development of a new viral vector manufacturing centre for Oxford BioMedica.
Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…
Roche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3…
Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.
Taiho Oncology got aproval to have its Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the United States.
BioMarin Pharmaceutical’s net loss for 2018 decreased $39.8 million or 34%, to $77.2 million, compared to $117.0 million in 2017, in part due to increase in gross profil of million.